Receipt of DTaP, IPV, PCV13, or Hib prior to enrollment. Previous administration of the first dose of HBV is permitted
Anticipated receipt of any vaccine other than DTaP, IPV, HBV, PCV13, or Hib during the first 60 hours after randomization
History of a severe allergic reaction (e.g. anaphylaxis) to a previous dose of any hepatitis B vaccine
History of a severe allergic reaction (e.g. anaphylaxis) to any component of the vaccines used in the study including neomycin, yeast and polymyxin B
History of latex allergy
History of unstable progressive neurologic disorder of unknown cause
Known cause of apnea other than apnea of prematurity
Cyanotic heart disease (congenital or acquired)
Child or parent/LAR is an immediate relative of study staff or an employee who is supervised by study staff.
Any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol

NCT03530124_exc_T1
Drug
DTaP
NCT03530124_exc_T2
Drug
IPV
NCT03530124_exc_T3
Drug
PCV13
NCT03530124_exc_T4
Drug
Hib
NCT03530124_exc_T5
Temporal
prior to enrollment
NCT03530124_exc_T6
Reference_point
enrollment
NCT03530124_exc_T7
Scope
DTaP, IPV, PCV13, or Hib
NCT03530124_exc_T8
Drug
DTaP
NCT03530124_exc_T9
Drug
IPV
NCT03530124_exc_T10
Drug
HBV
NCT03530124_exc_T11
Drug
PCV13
NCT03530124_exc_T12
Drug
Hib
NCT03530124_exc_T13
Mood
Anticipated receipt
NCT03530124_exc_T14
Temporal
during the first 60 hours after randomization
NCT03530124_exc_T15
Reference_point
randomization
NCT03530124_exc_T16
Scope
DTaP, IPV, HBV, PCV13, or Hib
NCT03530124_exc_T17
Qualifier
severe
NCT03530124_exc_T18
Condition
allergic reaction
NCT03530124_exc_T19
Condition
anaphylaxis
NCT03530124_exc_T20
Drug
hepatitis B vaccine
NCT03530124_exc_T21
Temporal
previous
NCT03530124_exc_T22
Scope
severe allergic reaction
NCT03530124_exc_T23
Qualifier
severe
NCT03530124_exc_T24
Condition
allergic reaction
NCT03530124_exc_T25
Condition
anaphylaxis
NCT03530124_exc_T26
Drug
component of the vaccines used in the study
NCT03530124_exc_T27
Drug
neomycin
NCT03530124_exc_T28
Drug
polymyxin B
NCT03530124_exc_T29
Drug
yeast
NCT03530124_exc_T30
Scope
neomycin, yeast and polymyxin B
NCT03530124_exc_T31
Scope
severe allergic reaction
NCT03530124_exc_T32
Condition
allergy
NCT03530124_exc_T33
Drug
latex
NCT03530124_exc_T34
Observation
History
NCT03530124_exc_T35
Condition
progressive neurologic disorder
NCT03530124_exc_T36
Qualifier
unknown cause
NCT03530124_exc_T37
Qualifier
unstable
NCT03530124_exc_T38
Observation
History
NCT03530124_exc_T39
Condition
Known cause of apnea
NCT03530124_exc_T40
Condition
apnea of prematurity
NCT03530124_exc_T41
Negation
other than
NCT03530124_exc_T42
Condition
Cyanotic heart disease
NCT03530124_exc_T43
Qualifier
congenital
NCT03530124_exc_T44
Qualifier
acquired
NCT03530124_exc_T45
Scope
congenital or acquired